Alternative Data for Liquidia
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 16 | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | 72 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 87 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 4,235 | Sign up | Sign up | Sign up |
| X Followers | 1,093 | Sign up | Sign up | Sign up |
| X Mentions | 80 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 47 | Sign up | Sign up | Sign up |
| Linkedin Employees | 214 | Sign up | Sign up | Sign up |
About Liquidia
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
| Price | $37.58 |
| Target Price | Sign up |
| Volume | 1,603,614 |
| Market Cap | $3.38B |
| Year Range | $12.19 - $46.63 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
Liquidia Q4 Earnings Call HighlightsMarch 5 - Yahoo Entertainment |
|
Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateMarch 5 - GlobeNewswire |
|
 |
Liquidia: Capturing Special Situation Gains And Longer-Term GainsJanuary 22 - SeekingAlpha |
 |
Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 15 - SeekingAlpha |
|
Liquidia Corporation (LQDA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14 - SeekingAlpha |
 |
Liquidia: Won Many Patent Battles But The War Is Not Yet WonJanuary 13 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 54M | 3.2M | 51M | -3.5M | 3.9M | -0.040 |
| Q2 '25 | 8.8M | 1.3M | 7.5M | -42M | -36M | -0.490 |
| Q1 '25 | 3.1M | 1.5M | 1.6M | -38M | -33M | -0.450 |
| Q4 '24 | 2.9M | 1.4M | 1.6M | -38M | -33M | -0.450 |
| Q3 '24 | 4.4M | 1.6M | 2.9M | -23M | -20M | -0.388 |
Insider Transactions View All
| Moomaw Scott filed to sell 188,954 shares at $35.3. March 11 '26 |
| Adair Jason filed to sell 212,479 shares at $30.6. March 3 '26 |
| Boyle Dana filed to sell 178,840 shares at $30.6. March 3 '26 |
| Krepp Sarah filed to sell 164,658 shares at $30.6. March 3 '26 |
| Moomaw Scott filed to sell 188,954 shares at $30.6. March 3 '26 |
Similar companies
Read more about Liquidia (LQDA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Liquidia
The Market Cap of Liquidia is $3.38B.
Currently, the price of one share of Liquidia stock is $37.58.
The LQDA stock price chart above provides a comprehensive visual representation of Liquidia's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Liquidia shares. Our platform offers an up-to-date LQDA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Liquidia (LQDA) does not offer dividends to its shareholders. Investors interested in Liquidia should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Liquidia are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
